Cargando…

Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital

Introduction: Cabazitaxel (CBZ) is used worldwide for castration-resistant prostate cancer after docetaxel treatment. In July 2014 the drug was approved in Japan with the same induction dose used for Caucasian patients. In this study, we examined and compared the results of an initial low-dose CBZ t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaya, Ryosuke, Okamura, Takehiko, Yanase, Takahiro, Nagai, Takashi, Moritoki, Yoshinobu, Kobayashi, Daichi, Akita, Hidetoshi, Yasui, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Association of Rural Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983453/ https://www.ncbi.nlm.nih.gov/pubmed/32015778 http://dx.doi.org/10.2185/jrm.2019-004

Ejemplares similares

Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients
por: Nagai, Takashi, et al.
Publicado: (2019)

A case of laparoscopic fenestration surgery for pelvic lymphocele occurring after laparoscopic radical prostatectomy
por: Oyama, Hiroki, et al.
Publicado: (2019)

Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy
por: Nagai, Takashi, et al.
Publicado: (2019)

Case of a giant gauzeoma diagnosed 21 years after an inguinal hernia surgery
por: Chaya, Ryosuke, et al.
Publicado: (2018)

A Study of Patients with Primary Mediastinal Germ Cell Tumors Treated Using Multimodal Therapy
por: Tanaka, Yutaro, et al.
Publicado: (2017)

Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy
por: Nagai, Takashi, et al.
Publicado: (2019)

Outcomes and Complications of Simultaneous Laparoscopic Cystectomy and Laparoscopic Nephroureterectomy with Umbilical Reduced Port Surgery
por: Tanaka, Yutaro, et al.
Publicado: (2018)

Primary diffuse large B‐cell lymphoma of the ileal conduit created after radical cystectomy
por: Nagai, Takashi, et al.
Publicado: (2018)

Extramedullary plasmacytoma of the ureter in an HIV-positive patient
por: Nagai, Takashi, et al.
Publicado: (2017)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Plasmacytoid Urothelial Carcinoma of the Bladder That Manifests Disseminated Carcinomatosis of the Bone Marrow: A Case Report of Extremely Rapid Progression
por: Shimizu, Nobuhiko, et al.
Publicado: (2022)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Therapeutic results in elderly patients with prostate cancer: chronological comparison in a single community hospital
por: Okamura, Takehiko, et al.
Publicado: (2016)

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients
por: Terada, Naoki, et al.
Publicado: (2019)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Seminomatous Extragonadal Germ Cell Tumor with Complete Obstruction of the Superior Vena Cava Responding to Intensive Chemotherapy
por: Moritoki, Yoshinobu, et al.
Publicado: (2011)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
por: Naiki, Taku, et al.
Publicado: (2012)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy
por: Uemura, Koichi, et al.
Publicado: (2017)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
por: Fryzek, Jon P., et al.
Publicado: (2018)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening
por: Haldrup, Jakob, et al.
Publicado: (2023)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
por: Rocha, Sandra M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hfnav606fcqk05nrl18h561dik